Products
Benzbromarone was withdrawn from the market in many countries in 2003 because of its hepatotoxicity. Desuric and other drugs are no longer available. It is still available in other countries. The withdrawal was not without controversy (Jansen, 2004).
Structure and properties
Benzobromarone (C17H12Br2O3, Mr = 424.1 g/mol) is a derivative of khellin. It exists as a white crystalline powder that is practically insoluble in water.
Effects
Benzbromarone (ATC M04AB03) is uricosuric. It promotes renal excretion of uric acid by inhibiting reabsorption at the nephron.
Indications
As a second-line agent for the treatment of hyperuricemia and gout.
Dosage
According to the SmPC. Tablets are administered after meals. Treatment is started gradually and sufficient fluids should be consumed.
Contraindications
Benzbromarone is contraindicated in hypersensitivity, impaired renal function, renal stone diathesis, liver disease, during pregnancy, secondary hyperuricemia secondary to hematologic disorders, and acute gout attack. For complete precautions, see the drug label.
Interactions
Benzbromarone should not be coadministered with hepatotoxic drugs. Salicylates and sulfinpyrazone may attenuate its effects.
Adverse Effects
The most common possible adverse effects include digestive disturbances such as nausea, vomiting, bloating, and diarrhea. Very rarely, severe hepatitis has been reported, sometimes with fatal outcome.
